Trial Profile
Phase II Study of Paricalcitol Injection Extension Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Haemodialysis With Secondary Hyperparathyroidism [EXTENSION OF 700245849]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Paricalcitol (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 18 Jun 2014 New trial record
- 12 Jan 2010
- 15 Feb 2009